Antibody–Drug Conjugates in TNBC

Download these slides for expert insights into approved and emerging antibody–drug conjugates for managing TNBC, including sacituzumab govitecan, ladiratuzumab vedotin, and more.
Kevin Kalinsky, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 1.79 MB
Released: December 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Related Content

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for HCC and BTCs

R. Kate Kelley, MD Amit G. Singal, MD, MS Released: January 27, 2021

From Clinical Care Options, download slides reviewing the integration of CAR T-cell therapy into community care

Michael R. Bishop, MD Jae H. Park, MD Released: January 26, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy into community care

Michael R. Bishop, MD Jae H. Park, MD Released: January 26, 2021

From Clinical Care Options (CCO), on-demand Webcast with Lee Schwartzberg, MD, FACP, and Ruth O’Regan, MD, on optimal treatment of breast cancer brain metastases

Ruth O'Regan, MD Lee Schwartzberg, MD, FACP Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue